Les Echos.fr - February 25, 2011
The French and BioMérieux Ipsen signed a partnership agreement for the development of personalized medicines in oncology, based on Ipsen's portfolio of innovative diagnostic tests and BioMérieux. Ipsen is already present in this area with Decapeptyl (treptorelina) for cancer of the prostate and breast cancers and in early stage clinical trials for cancer molecules in breast and endometrium.
0 comments:
Post a Comment